SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3561 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1335I'd never heard of him when I bought it. It came up in the Garren newslettertom pope-8/7/2007
1334Message 23767408 <<p.s. Re GENR, the company you say no one with half a bMiljenko Zuanic-8/7/2007
1333Humira is not better than Enbrel, still doing very well!Miljenko Zuanic-8/7/2007
1332<<Not that Dew needs any defense, but he was off GENR long before it becamMiljenko Zuanic-8/7/2007
1331<i>>They have an spa and this is a highly powered and robust trial desiDewDiligence_on_SI-8/6/2007
1330No question I agree to disagree. They have an spa and this is a highly powered arkrw-8/6/2007
1329<i>>But its obvious, anything in amd will have to be materially better DewDiligence_on_SI-8/6/2007
1328The problem for genentech is lucentis isn't sufficiently differentiated fromrkrw-8/6/2007
1327Not that Dew needs any defense, but he was off GENR long before it became a nightom pope-8/6/2007
1326You don't stay on topic particularly well. Heh, heh.scaram(o)uche-8/6/2007
1325OT: Dew, Ad Hominem attacks will always diminish the attacker much more than tIan@SI-8/6/2007
1324<i>>I understood Miljenko's point quite clearly, he doesn't conDewDiligence_on_SI-8/6/2007
1323[OT] <i>>You were calling me a "blowhard" at IHub, before youDewDiligence_on_SI-8/6/2007
1322>> I didn’t see you raise an etiquette objection when miljenko called me sscaram(o)uche-8/6/2007
1321I was at a wedding this weekend and saw a funny t-shirt, "welcome to americrkrw-8/6/2007
1320I'll agree that it's probably as difficult to change one's characternigel bates-8/6/2007
1319<i>>You might try the same with basic etiquette.<</i> LOL—I dDewDiligence_on_SI-8/6/2007
1318>>Take a freaking English course.<< You might try the same with basnigel bates-8/6/2007
1317<i>>This is far from "substantial proportion"!<</i> DewDiligence_on_SI-8/6/2007
1316With placebo adjustment 1/4 to 1/3 of the subjects do have improvement in visualMiljenko Zuanic-8/4/2007
1315<i>>Show data?<</i> It’s in Table 3 and Table 4 of the FDA LuDewDiligence_on_SI-8/4/2007
1314Jim, RE: DEW There is no limit to Human’s stubbornness (read this as “stupiditMiljenko Zuanic-8/3/2007
1313<<The success of Lucentis stems from the fact that it was the first AMD drMiljenko Zuanic-8/3/2007
1312Thanks on the lucentis info. I'm going to disagree with you on your primarrkrw-8/3/2007
1311The last sentence of msg #1306 should read: “What the trial design tells me isDewDiligence_on_SI-8/3/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News